Ibrahim AS - Search Results

1

Mucormycosis in 2023: an update on pathogenesis and management.

Alqarihi A, Kontoyiannis DP, Ibrahim AS. Alqarihi A, et al. Among authors: ibrahim as. Front Cell Infect Microbiol. 2023 Sep 21;13:1254919. doi: 10.3389/fcimb.2023.1254919. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37808914 Free PMC article. Review.

2

Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Spellberg B, Edwards J Jr, Ibrahim A. Spellberg B, et al. Clin Microbiol Rev. 2005 Jul;18(3):556-69. doi: 10.1128/CMR.18.3.556-569.2005. Clin Microbiol Rev. 2005. PMID: 16020690 Free PMC article. Review.

3

Deferiprone iron chelation as a novel therapy for experimental mucormycosis.

Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Ibrahim AS, et al. J Antimicrob Chemother. 2006 Nov;58(5):1070-3. doi: 10.1093/jac/dkl350. Epub 2006 Aug 23. J Antimicrob Chemother. 2006. PMID: 16928702

4

The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ. Ibrahim AS, et al. J Clin Invest. 2007 Sep;117(9):2649-57. doi: 10.1172/JCI32338. J Clin Invest. 2007. PMID: 17786247 Free PMC article.

5

Combination echinocandin-polyene treatment of murine mucormycosis.

Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B. Ibrahim AS, et al. Antimicrob Agents Chemother. 2008 Apr;52(4):1556-8. doi: 10.1128/AAC.01458-07. Epub 2008 Jan 22. Antimicrob Agents Chemother. 2008. PMID: 18212099 Free PMC article.

6

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.

Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, Spellberg B. Reed C, et al. Among authors: ibrahim as. Clin Infect Dis. 2008 Aug 1;47(3):364-71. doi: 10.1086/589857. Clin Infect Dis. 2008. PMID: 18558882 Free PMC article.

7

Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.

Ibrahim AS, Gebremariam T, Liu M, Chamilos G, Kontoyiannis D, Mink R, Kwon-Chung KJ, Fu Y, Skory CD, Edwards JE Jr, Spellberg B. Ibrahim AS, et al. J Infect Dis. 2008 Oct 1;198(7):1083-90. doi: 10.1086/591461. J Infect Dis. 2008. PMID: 18694335 Free PMC article.

8

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

Ibrahim AS, Edwards JE Jr, Bryant R, Spellberg B. Ibrahim AS, et al. Med Mycol. 2009;47(6):592-600. doi: 10.1080/13693780802326001. Med Mycol. 2009. PMID: 18798118 Free PMC article.

9

Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.

Ibrahim AS, Spellberg B, Edwards J Jr. Ibrahim AS, et al. Curr Opin Infect Dis. 2008 Dec;21(6):620-5. doi: 10.1097/QCO.0b013e3283165fd1. Curr Opin Infect Dis. 2008. PMID: 18978530 Free PMC article. Review.

10

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, Walsh TJ, Ibrahim AS. Spellberg B, et al. Among authors: ibrahim as. Antimicrob Agents Chemother. 2009 Jul;53(7):3122-5. doi: 10.1128/AAC.00361-09. Epub 2009 May 11. Antimicrob Agents Chemother. 2009. PMID: 19433555 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

395 results

Search Page